<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136223">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01965080</url>
  </required_header>
  <id_info>
    <org_study_id>NSGO-EC-0302</org_study_id>
    <nct_id>NCT01965080</nct_id>
  </id_info>
  <brief_title>Exemestane in Advanced and Recurrent Endometrial Carcinoma</brief_title>
  <official_title>Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Society for Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Society for Gynaecologic Oncology</source>
  <oversight_info>
    <authority>Norway: Norwegian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study of Exemestane in Advanced or recurrent endometrial carcinoma

      Hypothesis: Treatment With Exemestane can give a response rate of at least 30%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients With Advanced or recurrent endometrial cancer of endometrioid type were treated
      With Exemestane tablets 25 mg daily.

      Patients were grouped according to estrogen receptor status.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Objective response rate within 6 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Special attention to progression status at 6 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Toxicity</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Asses toxicity to the treatment using Common Toxicity Criteria for Adverse Effects</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exemestane 25 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>One tablet Exemestane 25 mg daily</description>
    <arm_group_label>Exemestane</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or recurrent endometrial cancer not considered for treatment modalities
             apart from hormonal treatment

          -  Endometrioid histology

          -  Age above 18 years

          -  Post menopausal status

          -  Performance status 0-2

          -  Informed consent

        Exclusion Criteria:

          -  Congestive heart disease grade III.IV

          -  History of thromboembolic signs

          -  Other primary hormonal therapy

          -  Patients With symptomatic brain metastasis

          -  Severe hepatic or renal impairment

          -  Pregnancy, lactation or child bearing potential without adequate contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Kristensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NSGO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 15, 2013</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endometrial cancer</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
